Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
Ann Rheum Dis. 2013 May; 72(5):741–4
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2013 May; 72(5):741–4
International Journal of Clinical Rheumatology June 2013; 8(3):311–13
The New England Journal of Medicine 2010; 363(14):1303-12
Arthritis & Rheumatism 2011; 63(2):337-45
Arthritis & Rheumatism 2012; 64(4):970-81
The New England Journal of Medicine 2012; 367(6):495-507
The New England Journal of Medicine 2012; 367(6):508-19
The Lancet 2013; 381(9865):451-60
Annals of Rheumatic Diseases 2013; doi:10.1136/annrheumdis-2012-202442